PEI联合抗病毒药物治疗HBV-DNA阳性原发性肝癌的临床研究  

Clinical study of PEI with Antiviral treatment for primary liver cancer with HBV-DNA positive

作　　者：王东盛[1] 王成纲[1] 陆英[1] 刘明[1] 刘海洋[1] 

机构地区：[1]北京煤炭总医院介入科,北京100028

出　　处：《中国医药导报》2011年第6期45-46,共2页China Medical Herald

摘　　要：目的:观察经皮无水酒精注射联合恩替卡韦治疗HBV-DNA阳性原发性肝癌患者的疗效。方法:60例HBV-DNA阳性原发性肝癌患者,随机分为两组,每组各30例。均给予PEI治疗。治疗组在常规保肝治疗基础上加用恩替卡韦,0.5mg/d;对照组常规保肝治疗。结果:PEI治疗3个月后,对照组病灶完全坏死率明显低于治疗组(P<0.05)。对照组肿瘤复发率明显高于治疗组(P<0.05)。对照组1年生存率明显低于治疗组(P<0.05)。治疗组HBV-DNA转阴率高于对照组(P=0.000)。结论:PEI联合恩替卡韦治疗HBV-DNA阳性原发性肝癌患者疗效良好,能有效改善患者的预后。Objective：To study the therapeutic efficacy of PEI with Entecavir for the patients with primary liver cancer with HBV-DNA positive.Methods：60 patients were devided into the treamtment group and the control group,they were treated by PEI.The treamtment group was treated by Entecavir.The control group was treamted by general remedy.Results：Three months later,the complete necrosis rate and recurrence rate were significantly difference in the treamtment group compared with the control group（P0.05）.The one year survival rate of the control group was lower than that in the treamtment group（P0.05）.The negative conversion ratio of HBV-NDA was reduced in the control group compared with the treamtment（P=0.000）.Conclusion：The therapeutic efficacy of PEI with Entecavir for patients with primary liver cancer with HBV-DNA positive is satisfied,that can improve prognosis of the patients with primary liver cancer after PEI.

关 键 词：经皮无水酒精注射 恩替卡韦 原发性肝癌 预后 

分 类 号：R735.7[医药卫生—肿瘤]